Blood test predicts which bladder cancer patients may safely skip surgery
Medical Xpress
February 28, 2026
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.
Verticals
healthmedical
Originally published on Medical Xpress on 2/28/2026